First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170,000 Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic technology company, today announced financial results for the ...

Core Insights - electroCore, Inc. announced that its flagship wellness product, Truvaga Plus, is now compatible with the Apple Health app, enhancing user experience and health management [1][2] - Truvaga Plus is a hand-held vagus nerve stimulator aimed at providing stress relief, improving sleep, enhancing peace of mind, and improving focus [1] - The integration with the Apple Health app allows users to track their health data, including their progress with Truvaga Plus, in a consolidated view [2] Product Features - Truvaga Plus enables users to log their feelings after each session, utilizing the State of Mind API to monitor mental wellbeing over time [2] - The Apple Health app provides a secure platform for users to store and access important health information, leveraging the privacy features of iPhones [3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive technologies [4]